InsidersTradesSigma
Follow the Lomond Therapeutics Holdings, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 5 November 2024 (C). Among the most active insiders: Savchuk Nikolay. Every trade is free.
Analysts rate Lomond Therapeutics Holdings, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Lomond Therapeutics Holdings, Inc. 是一家在 XNAS 市场上市的公司，专注于开发创新疗法。它专门从事特定疾病治疗解决方案的研发。